Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Revvity Inc. (NYSE:RVTY)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Revvity stock on May 4th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Revvity Price Performance

Revvity stock opened at $101.28 on Thursday. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The stock has a market cap of $11.30 billion, a P/E ratio of 48.46, a PEG ratio of 2.28 and a beta of 1.11. The company has a 50-day moving average price of $94.40 and a 200 day moving average price of $97.72. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $118.30.

Revvity (NYSE:RVTY) last announced its earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The company had revenue of $711.12 million during the quarter, compared to analyst estimates of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. Revvity’s revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Sell-side analysts anticipate that Revvity Inc. will post 5.25 earnings per share for the current year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, July 17th. Revvity’s dividend payout ratio (DPR) is presently 13.40%.

Institutional Trading of Revvity

Several hedge funds have recently added to or reduced their stakes in RVTY. Ascentis Independent Advisors acquired a new stake in Revvity in the first quarter valued at approximately $29,000. CYBER HORNET ETFs LLC acquired a new position in shares of Revvity in the 2nd quarter valued at $32,000. Cromwell Holdings LLC increased its holdings in shares of Revvity by 141.4% in the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after acquiring an additional 198 shares during the period. MUFG Securities EMEA plc acquired a new position in shares of Revvity in the 2nd quarter valued at $34,000. Finally, SJS Investment Consulting Inc. increased its holdings in shares of Revvity by 5,210.0% in the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after acquiring an additional 521 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Analysts Set New Price Targets

RVTY has been the subject of several research analyst reports. The Goldman Sachs Group lowered their target price on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a research note on Tuesday, April 14th. Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. TD Cowen increased their target price on shares of Revvity from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Robert W. Baird set a $117.00 target price on shares of Revvity in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $107.73.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.